Skip to Content

Collaborative Publications by SPORE Investigators Facilitated by This Grant

Note: Bold indicates an investigator affiliated with the MD Anderson Ovarian Cancer SPORE or an Ovarian Cancer SPORE at another institution.

  1. Yu Y, Xu F, Fang X, Zhao S, Li Y, Cuevas B, Kuo W-L, Gray JW, Siciliano M, Mills G, Bast RC Jr. NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci USA 1999; 96:214-219. PMCID: PMC15119.
  2. Furui T, LaPushin R, Mao M, Kahn H, Watt SR, Watt M-AV, Fang X, Tsutsui S, Siddik Z, Bast RC Jr, Mills GB. Overexpression of Edg-2/vzg-1 induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid independent manner. Clin Cancer Res 1999; 5:4308-4318. PMID: 10632375.
  3. Fang X, Yu S, Eder A, Mao M, Bast RC Jr, Boyd D, Mills GB. Regulation of BAD phosphorylation at serine 112 by the Ras-Mitogen-Activated Protein kinase pathway. Oncogene 1999;48:6635-6640. PMID: 10597268.
  4. Pustilnik TB, Estrella V, Wiener J, Mao M, Eder A, Watt M-AV, Boyd D, Bast RC, Jr, Mills GB. Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells. Clin Cancer Res 1999; 5:3704-3710. PMID: 10589790.
  5. Gershenson DM, Deavers M, Diaz S, Tortolero-Luna G, Miller B, Bast RC Jr, Mills GB, Silva E. Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors. Clin Cancer Res 1999; 5:4053-4058. PMID: 10632339.
  6. Wolf JK, Mills GB, Bast RC Jr, Roth JA, Gershenson DM. Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogneous p53 status. Gynecol Oncol 1999; 75:261-266. PMID: 10525383.
  7. Hagopian GS, Mills GB, Khokhar AR, Bast RC Jr, Siddik ZH. Studies of cisplatin (CDDP) resistance with 1R,2R-diaminocyclohexane (DACH)-diacetato-dichloro-Pt(IV) (acetato-Pt) in ovarian cancer cell lines. Clin Cancer Res 1999;5: 655-664. PMID: 10100719.
  8. Xu F-J, Yu YH, Le X-F, Boyer C, Mills GB, Bast RC Jr. The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression. Clin Cancer Res 1999; 5:3653-3660. PMID: 10589783.
  9. Kruzelock RP, Cuevas BD, Wiener JR, Xu F-J, Yu Y, Cabeza-Arvelaiz Y, Pershouse M, Lovell MM, Killary AM, Mills GB, Bast RC Jr. Functional evidence for an ovarian cancer tumor suppressor gene on chromosome 22 by microcell-mediated chromosome transfer. Oncogene 2000; 19:6277-6285. PMID: 11175342.
  10. Peng HQ, Xu F-J, Pershad R, Hogg D, Gray JW, Berchuck A, Bast RC Jr, Yu YH. ARHI is the center of allelic deletion on chromosome 1p31 in ovarian and breast cancers. Int J Cancer 2000; 86:690-694. PMID: 10797292.
  11. Fang X, LaPushin R, Lu Y, Furui T, Penn LZ, Stokoe D, Bast RC Jr, Mills GB. Lysophosphatidic acid prevents apoptosis in fibroblasts: dissection of proliferative and survival signals. Biochem J 2000; 352:135-143. PMCID: PMC1221440.
  12. Bast RC Jr, Yu Y, Xu F-J, Le X-F, Mills GB. Molecular approaches to management of epithelial ovarian cancer. Int J Gynecol Cancer 2000; 10 (Supplement 1):2-7. PMID: 11240724.
  13. Mao M, Fang X-J, Lu Y, Bast RC Jr., Mills GB. Inhibition of growth factor-induced phosphorylation and activation of PKB/AKT by atypical PKC zeta in breast cancer cells. Biochem J 2000; 352:475-482. PMCID: PMC1221479.
  14. Hu W, McCrea PD,  Deavers MKavanagh JJ, Kudelka AP, Verschragen CF. Increased expression of fascin, motility associated protein, in cell cultures derived from ovarian cancer and in borderline and carcinomatous ovarian tumors.  Clin Exp Metastasis 2000; 18(1): 83-8. PMID: 11206843.
  15. Le X-F, McWatters A, Wiener J, Wu, J-W, Mills GB, Bast RC, Jr. Anti-HER2 antibody and heregulin suppress growth of HER2-overexpressing human breast cancer cells through different mechanisms. Clin Cancer Res 2000; 6:260-270. PMID: 10656457.
  16. Donato M, Gershenson D, Ippoliti C, Wharton JT, Bast RC Jr, Aleman A, Anderlini P, Gajewski JG, Giralt S, Molldrem J, Ueno N, Lauppe, J, Korbling M, Boyer J, Bodurka-Bevers D, Bevers M, Burke T, Freedman R, Wolf J, Champlin RE. Intensive-dose ifosfamide and etoposide with filgastrim for cytoreduction prior to high-dose chemotherapy in patients with advanced ovarian cancer. Bone Marrow Transplantation 2000; 25:1137-1140. PMID: 10849525.
  17. Xu F, Xia W, Zhao S, Peng H, Luo R Z, Dai J, Long Y, Zhao L, Le W, Parlow A F, Hung MC, Bast RC Jr, Yu Y. ARHI acts as an inhibitor of growth and lactation in transgenic mice. Cancer Res 2000; 60:4913-20. PMID: 10987306.
  18. Bast RC Jr, Mills GB. Alterations in oncogenes, tumor suppressor genes and growth factors associated with epithelial ovarian cancers. In Methods in Molecular Medicine Vol. 39: Ovarian Cancer, ed. J.M.S. Bartlett, Humana Press, Totowa, New Jersey, 2000, pp 37-48. [no PMID]
  19. Verschraegen CG, Levenback C, Vincent M, Wolf JK, Bevers M, Loyer E, Kudelka AP, Kavanagh JJ. Phase II study of intravenous DX-8951f in patients with advanced ovarian, tubal, or peritoneal cancer refractory to platinum, taxane, and topotecan. Ann N Y Acad Sci 2000; 922:349-51. PMID: 11193920.
  20. Donato ML, Gershenson DM, Wharton JT, Iappoliti CM, Aleman AS, Bodurka-Bevers D, Bevers MW, Burke TW, Levenback C, Wolf JK, Freeman RS, Bast RC Jr, Gajewski JL, Champlin RE. High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer. Gynecol Oncol 2001; 82(3):420-6. PMID: 11520135.
  21. Robinson JB, Singh D, Bodurka-Bevers DC, Wharton JT, Gershenson DM, Wolf JK. Hypersensitivity reaction and the utility of oral and intravenous desensitization in patients with gynecologic malignancies. Gynecol Oncol 2001; 82(3):550-8. PMID: 11520154.
  22. Munkarah A, Levenback C, Wolf JK, Bodurka-Bevers D, Tortolero-Luna G, Morris RT, Gershenson DM. Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer. Gynecol Oncol 2001; 81(2);237-41. PMID: 11330956.
  23. Modesitt SC, Ramirez P, Zu Z, Bodurka-Bevers D, Gershenson DM, Wolf JK. In vitro and in vivo adenovirus-mediated p53 and p16 tumor suppressor therapy in ovarian cancer. Clin Cancer Res 2001; 7(6):1765-72. PMID: 11410518.
  24. Brewer M, Utzinger U, Satterfield W, Gershenson D, Bast RC Jr, Wharton JT, Richards-Kortum R, Follen M. Biomarker modulation in a non-human rhesus model for ovarian cancer chemoprevention. Cancer Epidemiol Biomarkers Prevention 2001; 10:889-93. PMID: 11489756.
  25. Bast RC, Jr, Mills GB. The molecular pathogenesis of ovarian cancer. In: The Molecular Basis of Cancer, 2nd edition, J. Mendelsohn, P. Howley, M. Israel, L. Liotta (eds.), W.B. Saunders Co., 2001:361-384. [no PMID]
  26. Utzinger U, Brewer M, Silva E, Gershenson D, Bast RC Jr, Mitchell MF, Richards-Kortum R. Reflectance spectroscopy for in vivo characterization of ovarian tissue. Lasers Surg Med 2001; 28:56-66. PMID: 11430444.
  27. Le X-F, Marcelli M, McWatters A, Nan B, Mills GB, O’Brian CA, Bast RC Jr. Heregulin-induced apoptosis is mediated by down-regulation of Bcl-2 and activation of caspase-7 and is potentiated by impairment of protein kinase C Alpha Imageactivity, Oncogene 2001: 20:8258-69. PMID: 11781840.
  28. Parker LP, Ramirez PT, Broaddus R, Sightler S, Wolf JK. Low-grade ovarian cancer in an adolescent patient. Gynecol Oncol 2001; 80(1):104-6. PMID: 11136580.
  29. Erickson JR, Hasegawa Y, Fang X, Eder A, Mao M, Furui T, Aoki J, Morris A, Mills GB. Lysophosphatidic acid and ovarian cancer: a paradigm for tumorigenesis and patient management. Prostaglandins & Other Lipid Mediators 2001 64(1-4):63-81. PMID: 11331096 and PMID 11324708.
  30. Modesitt SC, Tortolero-Luna G, Robinson JB, Gershenson DM, Wolf JK. Ovarian and extraovarian endometriosis-associated cancer. Obstet Gynecol 2002; 100(4):788-95. PMID: 12383550.
  31. Bao J, Le XF, Wang RY, Yuan J, Wang L, LaPushin R, Andreeff M, Fang B, Yu Y, Bast RC. Re-expression of the tumor suppressor gene ARHI induces apoptosis in ovarian and breast cancer cells through a caspase-independent calpain-dependent pathway. Cancer Res 2002; 62:7264-72. PMID: 12499268.
  32. Petricoin III EF, Ardekani A, Hitt BA, Levine PJ, Steinberg SM, Mills GB, Simone CB, Fishman D, Kohn EC, Liotta LA. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 369:572-9. PMID: 11867112.
  33. *Mills GB, Eder A, Fang X, Hasegawa Y, Mao M, Lu Y, Tanyi J, Tabassam FH, Wiener J, Lapushin R, Yu S, Parrott JA, Compton T, Tribley W, Fishman D, Stack MS, Gaudette D, Jaffe R, Furui T, Aoki J, Erickson JR. Critical role of lysophospholipids in the pathophysiology, diagnosis and management of ovarian cancer. Cancer Treat Res 2002; 107:259-83. PMID: 11775454.
  34. Fang X, Schummer M, Mao M, Yu S, Tabassam FH, Swaby R, Hasegawa Y, Tanyi JL, LaPushin R, Eder A, Jaffe R, Erickson J, Mills GB. Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim Biophys Acta. 2002; 12582:257-64. PMID: 12069836.
  35. Wiener JR, Windham TC, Estrella VC, Parikh NU, Thall PF, Deavers MT, Bast RC Jr, Mills GB, Gallick G. Activated Src protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol Oncol 2003; 88:73-79. PMID: 12504632.
  36. Brewer M, Johnson K, Folen M, Gershenson D, Bast RC Jr. Prevention of Ovarian Cancer Intraepithelial Neoplasia, Clin Cancer Res 2003; 9:20-30. PMID: 12538447.
  37. Kim JH, Herlyn D, Wong KK, Park DC, Schorge JO, Lu KH, Skates SJ, Cramer DW, Berkowitz RS, Mok SC. Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer. Clin Cancer Res 2003; 9(13):4782-91. PMID: 14581349.
  38. Luo RZ, Fang X, Marquez R, Mills GB, Liao WSL, Yu Y, Bast RC, Jr. ARHI is a ras-related small G-protein with a novel N-terminal extension that inhibits growth of ovarian and breast cancers. Oncogene 2003; 22:2897-909. PMID: 12771940.
  39. Verschraegen CF, Hu W, Du Y, Mendoza J, Early J, Freedman RS, Bast RC, Jr., Kudelka AP, Kavanagh JJ, Giovanella BC. Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic ovarian cancers. Clinical Cancer Res 2003; 9(2):845-52. PMID: 12576458.
  40. Deavers MT, Malpica A, Ordonez NG, Silva EG.  Ovarian steroid cell tumors: an immunohistochemical study including a comparison of calretinin with inhibin.  Int J Gynecol Pathol 2003;  22(2): 162-7. PMID: 12649671.
  41. Bast RC, Mills GB. Molecular therapeutics and pharmocogenomics. Gynecol Oncol 2003; 88:S84-7. PMID: 12586093.
  42. Ozols RF, Daly MB, Klein-Szanto A, HamiltonTC, Bast RC, Brewer MA. Chemoprevention of ovarian cancer: The journey begins. Gynecol Oncol 2003; 88:S59-66. PMID: 12586088.
  43. Bodurka DC, Levenback C, Wolf JK, Gano J, Wharton JT, Kavanagh JJ, Gershenson DM. Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. J Clin Oncol 2003; 21(2):291-7. PMID: 12525521.
  44. Balkwill F, Bast RC, Berek J, Chenevix-Trench G, Gore M, Hamilton T, Jacobs I, Mills G, Souhami R, Urban N, Ursulic S, Smyth J. Current research and treatment for epithelial ovarian cancer. A position paper from the Helene Harris Memorial Trust. Eur J Cancer 2003 39:1818-27. PMID: 12932658.
  45. Wang L, Hoque A, Luo R, Yuan J, Liu J, Sahin A, Lippman S, Bast RC Jr, Yu Y. Loss of the expression of the tumor suppressor gene ARHI is associated with the progression of breast cancer. Clin Cancer Res 2003; 9:3660-6. PMID: 14506155.
  46. See HT, Kavanagh JJ, Hu W, Bast RC Jr. Targeted therapy for epithelial ovarian cancer: current status and future prospects. Int J Gynecol Cancer 2003; 13:701-34. PMID: 14675307.
  47. *Qian L, Xu Y, Hasegawa Y, Aoki J, Mills GB, Prestwich GD. Enantioselective responses to a phosphorothioate analogue of lysophosphatidic acid with LPA3 receptor-selective agonist activity. J Med Chem 2003; 46(26)5575-8. PMID: 14667211.
  48. *Tanyi JL, Hasegawa Y, Lapushin R, Morris AJ, Wolf JK, Berchuck A, Lu K, Smith DI, Kalli K, Hartmann LC, McCune K, Fishman D, Broaddus R, Cheng KW, Atkinson EN, Yamal JM, Bast RC, Felix EA, Newman RA, Mills GB. Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer. Clin Cancer Res 2003; 8: 3534-45. PMID: 14506139.
  49. *Tanyi JL, Moris AJ, Wolf JK, Fang X, Hasegawa Y, Lapushin R, Auersperg N, Sigal YJ, Newman RA, Felix EA, Atkinson EN, Mills GB. The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer. Cancer Res 2003; 63:1073-82. PMID: 12615725.
  50. *Mills GB, Fang X, Lu Y, Hasegawa Y, Eder A, Tanyi J, Tabassam FH, Erickson J, Gershenson D, Kohn E, Jaffe R, Bast RC Jr, Gray J. Molecular therapeutics in ovarian cancer. Gynecol Oncol 2003; 88: S88-S92. PMID: 12586094.
  51. Penson RT, Oliva E, Skates SJ, Glyptis T, Fuller AF Jr, Goodman A, Seiden MV. Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol Oncol. 2004 Apr;93(1):98-106. PMID: 15047220.
  52. Terry KL, Sluss PM, Skates SJ, Mok SC, Ye B, Vitonis AF, Cramer DW. Blood and urine markers for ovarian cancer: a comprehensive review. Dis Markers. 2004;20(2):53-70. Review. No abstract available. PMID: 15322314.
  53. Donato M, Aleman A, Champlin RE, Saliba RM, Wharton JT, Burke TW, Bodurka D, Bevers MW, Levenback CF, Wolf JK, Brewer M, Freedman RS, Ippoliti C, Bast RC Jr, Gajewski JL, Gershenson DM. Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation. Bone Marrow Transplantation. 2004; 33:1219-24. PMID: 15122311.
  54. Bast RC Jr, Mills GB, Molecular mechanisms of pathogenesis and progression of epithelial ovarian cancer. In: The Ovary, 2nd edition, PC Leung, EY Adashi (eds.) Elsevier Science, 2004: 425-445. [no PMID]
  55. Soliman PT, Slomovits BM, Broaddus RR, Sun CC, Oh JC, Eifel PJ, Gershenson DM, Lu KH. Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases. Gynecol Onc 2004; 94(2): 456-62. PMID: 15297188.
  56. Wolf JK, Bodurka DC, Gano KB, Deavers M, Ramondetta L, Ramirez PT., Levenback C, Gershenson DM. A phase I study of Adp53 (INGN201:ADVEXIN) for patients with platinum and paclitaxel-resistant epithelial ovarian cancer. Gynecol Oncol 2004; 94(2): 442-8. PMID: 15297186.
  57. Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM, Silva EG. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 2004; 28(4): 496-504. PMID: 15087669.
  58. Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A, Kaye SB; Scottish Gynaecological Cancer Trials Group. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004 Nov 17;96(22):1682-91. PMID: 15547181.
  59. Ramirez PT, Frumovitz M, Wolf JK, Levenback C. Laparoscopic port-site metastases in patients with gynecological malignancies. Int J Gynecol Cancer. 2004 Nov-Dec;14(6):1070-7. Review. PMID: 15571612.
  60. Bhoola SM, Coleman RL, Herzog T, Morris R, Bryant C, Estes JM, Alvarez RD. Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer. Gynecol Oncol. 2004 Dec;95(3):564-9. PMID: 15581964.
  61. Cheng KW, Lahad JP, Kuo WL, Lapuk A, Yamada K, Auersperg N, Liu J, Smith-McCune K, Lu KH, Fishman D, Gray JW, Mills GB. The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med 2004; 10:1251-6. PMID: 15502842.
  62. Hu W, Wu W, Kobayashi R, Kavanagh JJ. Proteomics in cancer screening and management in gynecologic cancer. Curr Oncol Rep. 2004 Nov;6(6):456-62. Review. PMID: 15485615.
  63. *Umeza-Goto M, Tanyi J, Lahad J Liu S, Lapushin R, Hasegawa Y, Lu Y, Trost R, Bevers T, Jonasch E, Aldape K, Liu J, James RD, Ferguson CG, Xu Y, Prestwich GD, Mills GB. Lysophosphatidic acid production and action: validated targets in cancer? J. Cell Biochem 2004; 92(6): 1115-40. PMID: 15258897.
  64. Le-X-F, Lammayot A, Gold D, Lu Y, Deshpande D, Chang T, Mills GB, Bast RC Jr. Genes affecting cycle, growth/maintenance and drug sensitivity are preferentially regulated by anti-HER 2 antibody through PI3K-AKT signaling. J Biol Chem. 2005 Jan 21;280(3):2092-104. Epub 2004 Oct 25. PMID: 15504738.
  65. Rosen DG, Yang G Qi C, Bast RC Jr, Gershenson DM, Silvio M, Liu J. Subcellular localization of p27KIPI expression predicts poor survival in human ovarian cancer, Clin Cancer Res, 2005 Jan 15;11(2 Pt 1):632-7. PMID: 15701850.
  66. Brown J, Shvartsman H, Deavers M, Ramondetta L, Burke T, Munsell M, Gershenson D. The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors. Gynecol Oncol, 2005 May;97(2):489-96. PMID: 15863149.
  67. Xu Y, Aoki J, Shimizu K, Umezu-Goto M, Hama K, Takanezawa YS, Mills GB, Arai H, Qian L, Prestwich GD. Structure activity relationships of Fluorinated Lysophosphatidic Acid Analogues: Discovery of High-Affinity LPA3 receptor agonists. J Med Chem 2005 May 5;48(9):3319-27. PMID: 15857137.
  68. Dong J, Peng J, Zhang H, Mondesire WH, Jian W, Mills GB, Hung MC, Meric-Bernstam F. The role of GSK3β in rapamycin mediated cell cycle regulation and chemosensitivity. Cancer Research 2005 Mar 1;65(5):1961-72. PMID: 15753396.
  69. Spitz MR, Wu X, Mills G. Integrative epidemiology: from risk assessment to outcome prediction. J Clin Oncol 2005; 23:267-75. PMID: 15637390.
  70. Hartmann L, Lu K, Linette G, Cliby W, Kalli K, Gershenson D, Bast R, Stec J, Iartchouk N, Smith D, Ross J, Hoersch S, Shridhar V, Lillie J, Kaufmann S, Clark E, Damokosh A. Gene expression profiles predict early relapse in ovarian cancer following platinum-paclitaxel chemotherapy. Clin Cancer Res, 2005 Mar 15;11(6):2149-55. PMID: 15788660.
  71. Lu KH, Dinh M, Kohlmann W, Watson P, Green J, Syngal S, Bandipalliam P, Chen LM, Allen B, Conrad P, Terdiman J, Sun C, Daniels M, Burke T, Gershenson DM, Lynch H, Lynch P, Broaddus RR. Gynecologic cancer as a "sentinel cancer" for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol. 2005 Mar;105(3):569-74. PMID: 15738026.
  72. See HT, Freedman RS, Kudelka AP, Burke TW, Gershenson DM, Tangjitgamol S, Kavanagh JJ. Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance. Int J Gynecol Cancer. 2005 Mar-Apr;15(2):209-16. PMID: 15823101.
  73. Dark GG, Calvert AH, Grimshaw R, Poole C, Swenerton K, Kaye S, Coleman R, Jayson G, Le T, Ellard S, Trudeau M, Vasey P, Hamilton M, Cameron T, Barrett E, Walsh W, McIntosh L, Eisenhauer EA. Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group. J Clin Oncol. 2005 Mar 20;23(9):1859-66. Epub 2005 Feb 7. PMID: 15699482.
  74. Kavanagh JJ, Gershenson DM, Choi H, Lewis L, Patel K, Brown GL, Garcia A, Spriggs DR. Multi-institutional phase 2 study of TLK286 (TELCYTA, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer. Int J Gynecol Cancer. 2005 Jul-Aug;15(4):593-600. PMID: 16014111.
  75. Fujiwara K, Markman M, Morgan M, Coleman RL. Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer. Gynecol Oncol. 2005 Apr;97(1):10-5. Review. PMID: 15790431.
  76. Sun CC, Bodurka DC, Weaver CB, Rasu R, Wolf JK, Bevers MW, Smith JA, Wharton JT, Rubenstein EB. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer. 2005 Apr;13(4):219-27. Epub 2004 Nov 9. PMID: 15538640.
  77. Hu W, Kavanagh JJ, Deaver M, Johnston DA, Freedman RS, Verschraegen CF, Sen S. Frequent overexpression of STK15/Aurora-A/BTAK and chromosomal instability in tumorigenic cell cultures derived from human ovarian cancer. Oncol Res. 2005;15(1):49-57. PMID: 15839305.
  78. Coleman RL. Phase III Clinical Trial of Maintenance Therapy for Patients with Ovarian Cancer. Curr Oncol Rep. 2005 Nov;7(6):417-8. No abstract available. [no PMID]
  79. Lu KH, Gershenson DM. Update on the management of ovarian germ cell tumors. J Reprod Med. 2005 Jun;50(6):417-25. PMID: 16050566.
  80. Stevens T, Brown J, Zander D, Bevers M, Gershenson D, Ramondetta L. Case Report: Adult granulosa cell tumors of the ovary in two first-degree relatives. Gynecol Oncol. 2005 Sep;98(3):502-5. PMID: 15992917.
  81. Brewer M, Wharton J, Wang J, McWatters A, Auersperg N, Gershenson D, Bast R, Zou C. In vitro model of normal, immortalized ovarian surface epithelial cells and ovarian cancer cells for chemoprevention of ovarian cancer. Gynecol Oncol. 2005 Aug;98(2):182-92. PMID: 15907982.
  82. Menon U, Skates SJ, Lewis S, Rosenthal AN, Rufford B, Sibley K, Macdonald N, Dawnay A, Jeyarajah A, Bast RC Jr, Oram D, Jacobs IJ. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol. 2005 Nov 1;23(31):7919-26. PMID: 16258091.
  83. Landen CN, Kinch MS, Sood AK. EphA2 as a target for ovarian cancer therapy. Expert Opin Ther Targets. 2005 Dec;9(6):1179-87. PMID: 16300469.
  84. Soliman PT, Broaddus RR, Schmeler KM, Daniels MS, Gonzalez D, Slomovitz BM, Gershenson DM, Lu KH. Women with synchronous primary cancers of the endometrium and ovary: do they have Lynch syndrome? J Clin Oncol. 2005 Dec 20;23(36):9344-50. PMID: 16361634.
  85. Halder J, Landen CN Jr, Lutgendorf SK, Li Y, Jennings NB, Fan D, Nelkin GM, Schmandt R, Schaller MD, Sood AK. Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells. Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8829-36. PMID: 16361572.
  86. Lu HK, Broaddus RR. Gynecologic Cancers in Lynch Syndrome/HNPCC. Fam Cancer. 2005;4(3):249-54. Review. PMID: 16136386.
  87. Han LY, Landen CN Jr, Kamat AA, Lopez A, Bender DP, Mueller P, Schmandt R, Gershenson DM, Sood AK. Preoperative Serum Tissue Factor Levels Are an Independent Prognostic Factor in Patients With Ovarian Carcinoma. J Clin Oncol.2006 Feb 10;24(5):755-61. Epub 2005 Dec 27. PMID: 16380413.
  88. Kuo MT, Wei Y, Yang X, Tatebe S, Liu J, Troncoso P, Sahin A, Ro JY, Hamilton SR, Savaraj N. Association of fragile site-associated (FSA) gene expression with epithelial differentiation and tumor development. Biochem Biophys Res Commun. 2006 Feb 17;340(3):887-93. Epub 2005 Dec 27. PMID: 16386706.
  89. Mei FC, Young TW, Liu J, Cheng X. RAS-Mediated epigenetic inactivation of OPCML in oncogenic transformation of human ovarian surface epithelial cells. FASEB J. 2006 Mar;20(3):497-9. Epub 2005 Dec 29. PMID: 16384911.
  90. Reed NS, Poole CJ, Coleman R, Parkin D, Graham JD, Kaye SB, Ostrowski J, Duncan I, Paul J, Hay A. A randomized comparison of treosulfan and carboplatin in patients with ovarian cancer: A study by the Scottish Gynaecological Cancer Trials Group (SGCTG). Eur J Cancer. 2006 Jan;42(2):179-85. Epub 2005 Dec 6. PMID: 16337372.
  91. Rosen DG, Yang G, Bast RC Jr, Liu J. Use of ras-transformed human ovarian surface epithelial cells as a model for studying ovarian cancer. Methods Enzymol. 2005;407:660-76. PMID: 16757360.
  92. Cheng YC, Saliba RM, Rondon G, Giralt SA, Lu KH, Bodurka DC, Gershenson DM, Champlin RE, Ueno NT. Low prevalence of premature ovarian failure in women given reduced-intensity conditioning regimens for hematopoietic stem-cell transplantation. Haematologica. 2005 Dec;90(12):1725-6. PMID: 16330461.
  93. Yu Y, Luo R, Lu Z, Wei Feng W, Badgwell D, Issa JP, Rosen DG, Liu J, Bast RC Jr. Biochemistry and Biology of ARHI (DIRAS3), an Imprinted Tumor Suppressor Gene Whose Expression Is Lost in Ovarian and Breast Cancers. Methods Enzymol. 2005;407:455-68. PMID: 16757345.
  94. Cheng KW, Lu Y, Mills GB. Assay of Rab25 function in ovarian and breast cancers. Methods Enzymol. 2005;403:202-15. PMID: 16473588.
  95. Sood AK, Bhatty R, Kamat AA, Landen CN, Han L, Thaker PH, Li Y, Gershenson DM, Lutgendorf S, Cole SW. Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res. 2006 Jan 15;12(2):369-75. PMID: 16428474.
  96. Hennessy BT, Nanjundan M, Cheng KW, Nolden L, Mills GB. Ovarian Cancer: Identification of remodeling and spacing factor 1 (rsf-1, HBXAP) at chromosome 11q13 as a putative oncogene in ovarian cancer. Eur J Hum Genet. 2006 Apr;14(4):381-3. PMID: 16418735.
  97. Schmeler KM, Lynch HT, Chen LM, Munsell MF, Soliman PT, Clark MB, Daniels MS, White KG, Boyd-Rogers SG, Conrad PG, Yang KY, Rubin MM, Sun CC, Slomovitz BM, Gershenson DM, Lu KH. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med. 2006 Jan 19;354(3):261-9. PMID: 16421367.
  98. Gallion H, Christopherson WA, Coleman RL, Demars L, Herzog T, Hosford S, Schellhas H, Wells A, Sevin BU. Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay. Int J Gynecol Cancer. 2006 Jan-Feb;16(1):194-201. PMID: 16445633.
  99. Vasey PA, Atkinson R, Osborne R, Parkin D, Symonds R, Paul J, Lewsley L, Coleman R, Reed NS, Kaye S, Rustin GJ. SCOTROC 2A: carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer. Br J Cancer. 2006 Jan 16;94(1):62-8. PMID: 16404361.
  100. Prowse AH, Manek S, Varma R, Liu J, Godwin AK, Maher ER, Tomlinson IP, Kennedy SH. Molecular genetic evidence that endometriosis is a precursor of ovarian cancer. Int J Cancer. 2006 Aug 1;119(3):556-62. PMID: 16506222.
  101. Herzog TJ, Coleman RL, Markman M, Cella D, Thigpen JT. The role of maintenance therapy and novel taxanes in ovarian cancer. Gynecol Oncol. 2006 Aug;102(2):218-25. Epub 2006 Feb 7. Review. PMID: 16460787.
  102. Rosen DG, Yang G, Deavers MT, Malpica A, Kavanagh JJ, Mills GB, Liu J. Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma. Cancer. 2006 May 1;106(9):1925-32. PMID: 16568440.
  103. Lee EJ, Deavers MT, Hughes JI, Lee JH, Kavanagh JJ. Metastasis to sigmoid colon mucosa and submucosa from serous borderline ovarian tumor: response to hormone therapy. Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:295-9. PMID: 16515607.
  104. See HT, Thomas DA, Bueso-Ramos C, Kavanagh J. Secondary leukemia after treatment with paclitaxel and carboplatin in a patient with recurrent ovarian cancer. Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:236-40. PMID: 16515597.
  105. Brewer M, Kirkpatrick ND, Wharton JT, Wang J, Hatch K, Auersperg N, Utzinger U, Gershenson D, Bast R, Zou C. 4-HPR modulates gene expression in ovarian cells. Int J Cancer. 2006 Sep 1; 119(5): 1005-13. PMID: 16570282.
  106. Wolf JK, Bodurka DC, Verschraegen C, Sun CC, Branham D, Jenkins AD, Atkinson N, Gershenson DM. A Phase II trial of oral capecitabine in patients with platinum - and taxane - refractory ovarian, fallopian tube, or peritoneal cancer. Gynecol Oncol. 2006 Sep;102(3):468-74. Epub 2006 Mar 3. PMID: 16516276.
  107. Lu Z, Luo RZ, Peng H, Rosen DG, Atkinson EN, Warneke C, Huang M, Nishmoto A, Liu J, Liao WS, Yu Y, Bast RC Jr. Transcriptional and posttranscriptional down-regulation of the imprinted tumor suppressor gene ARHI (DRAS3) in ovarian cancer. Clin Cancer Res. 2006 Apr 15;12(8):2404-13. PMID: 16638845.
  108. Wang X, Fu S, Freedman RS, Kavanagh JJ. Venous thromboembolism syndrome in gynecological cancer. Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:458-71. PMID: 16515646.
  109. Bussey KJ, Chin K, Lababidi S, Reimers M, Reinhold WC, Kuo WL, Gwadry F, Ajay, Kouros-Mehr H, Fridlyand J, Jain A, Collins C, Nishizuka S, Tonon G, Roschke A, Gehlhaus K, Kirsch I, Scudiero DA, Gray JW, Weinstein JN. Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol Cancer Ther. 2006 Apr;5(4):853-67. PMID: 16648555.
  110. Wang H, Rosen DG, Wang H, Fuller GN, Zhang W, Liu J. Insulin-like growth factor-binding protein 2 and 5 are differentially regulated in ovarian cancer of different histologic types. Mod Pathol. 2006 Sep;19(9):1149-56. Epub 2006 May 26. PMID: 16729015.
  111. Broaddus RR, Lu KH. Women with HNPCC: a target population for the chemoprevention of .gynecologic cancers. Front Biosci. 2006 Sep 1;11:2077-80. PMID: 16720294.
  112. Wen XF, Yang G, Mao W, Thornton A, Liu J, Bast RC, Le XF. HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene. 2006 Nov 2;25(52):6986-96. Epub 2006 May 22. PMID: 16715132.
  113. Ramirez PT, Slomovitz BM, McQuinn L, Levenback C, Coleman RL. Role of appendectomy at the time of primary surgery in patients with early-stage ovarian cancer. Gynecol Oncol. 2006 Dec;103(3):888-90. Epub 2006 Jun 27. PMID: 16806436.
  114. Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M, Merritt WM, Lin YG, Mangala LS, Kim TJ, Coleman RL, Landen CN, Li Y, Felix E, Sanguino AM, Newman RA, Lloyd M, Gershenson DM, Kundra V, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med. 2006 Aug;12(8):939-44. Epub 2006 Jul 23. PMID: 16862152.
  115. Rosen DG, Cai KQ, Luthra R, Liu J. Immunohistochemical staining of hMLH1 and hMSH2 reflects microsatellite instability status in ovarian carcinoma. Mod Pathol. 2006 Nov;19(11):1414-20. Epub 2006 Aug 25. PMID: 16941012.
  116. Halder J, Kamat AA, Landen CN Jr, Han LY, Lutgendorf SK, Lin YG, Merritt WM, Jennings NB, Chavez-Reyes A, Coleman RL, Gershenson DM, Schmandt R, Cole SW, Lopez-Berestein G, Sood AK. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res. 2006 Aug 15;12(16):4916-24. PMID: 16914580.
  117. Coleman RL, Sood AK. Historical Progress in the Initial Management of Ovarian Cancer: Intraperitoneal Chemotherapy. Curr Oncol Rep. 2006 Nov;8(6):455-64. PMID: 17040624.
  118. Kamat AA, Bischoff FZ, Dang D, Baldwin MF, Han LY, Lin YG, Merritt WM, Landen CN, Lu C, Gershenson DM, Simpson JL, Sood AK. Circulating Cell-Free DNA: A Novel Biomarker for Response to Therapy in Ovarian Carcinoma. Cancer Biol Ther. 2006 Oct;5(10):1369-74. Epub 2006 Oct 26. PMID: 16969071.
  119. Landen CN Jr, Lu C, Han LY, Coffman KT, Bruckheimer E, Halder J, Mangala LS, Merritt WM, Lin YG, Gao C, Schmandt R, Kamat AA, Li Y, Thaker P, Gershenson DM, Parikh NU, Gallick GE, Kinch MS, Sood AK. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J Natl Cancer Inst. 2006 Nov 1;98(21):1558-70. PMID: 17077358.
  120. Merritt WM, Thaker PH, Landen CN, Deavers MT, Fletcher MS, Lin YG, Han LY, Kamat AA, Schmandt R, Gershenson DM, Kinch MS, Sood AK. Analysis of EphA2 Expression and Mutant p53 in Ovarian Carcinoma. Cancer Biol Ther. 2006 Oct;5(10):1357-60. Epub 2006 Oct 31. PMID: 16969087.
  121. Morgan RJ Jr, Alvarez RD, Armstrong DK, Chen LM, Copeland L, Fowler J, Gaffney DK, Gershenson D, Greer BE, Johnston C, Lancaster JM, Lele S, Matulonis U, Ozols RF, Remmenga SW, Sabbatini P, Soper J, Teng N; National Comprehensive Cancer Network. Ovarian cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006 Oct;4(9):912-39. PMID: 17020669.
  122. Davidson B, Zhang Z, Kleinberg L, Li M, Flørenes VA, Wang TL, Shih IeM. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):5944-50. PMID: 17062665.
  123. Park JT, Li M, Nakayama K, Mao TL, Davidson B, Zhang Z, Kurman RJ, Eberhart CG, Shih IeM, Wang TL. Notch3 gene amplification in ovarian cancer. Cancer Res. 2006 Jun 15;66(12):6312-8. PMID: 16778208.
  124. Ye B, Skates S, Mok SC, Horick NK, Rosenberg HF, Vitonis A, Edwards D, Sluss P, Han WK, Berkowitz RS, Cramer DW. Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin Cancer Res. 2006 Jan 15;12(2):432-41. PMID: 16428483.
  125. Wang X, Fu S, Freedman RS, Liu J, Kavanagh JJ. Immunobiology of gestational trophoblastic diseases.  Int J Gynecol Cancer. 2006 Jul-Aug;16(4):1500-15. Review. PMID: 16884358.
  126. Nanjundan M, Zhang F, Schmandt R, Smith-McCune K, Mills GB. Identification of a novel splice variant of AML1b in ovarian cancer patients conferring loss of wild-type tumor suppressive functions. Oncogene. 2007 Apr 19;26(18):2574-84. Epub 2006 Oct 30. PMID: 17072347.
  127. Rosen DG, Mercado-Uribe I, Yang G, Bast RC Jr, Amin HM, Lai R, Liu J. The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis. Cancer. 2006 Dec 1;107(11):2730-40. PMID: 17063503.
  128. Silva EG, Gershenson DM, Malpica A, Deavers M. The Recurrence and the Overall Survival Rates of Ovarian Serous Borderline Neoplasms With Noninvasive Implants is Time Dependent. Am J Surg Pathol. 2006 Nov;30(11):1367-1371. PMID: 17063075.
  129. Yang G, Rosen DG, Colacino JA, Mercado-Uribe I, Liu J. Disruption of the retinoblastoma pathway by small interfering RNA and ectopic expression of the catalytic subunit of telomerase lead to immortalization of human ovarian surface epithelial cells. Oncogene. 2007 Mar 1;26(10):1492-8. Epub 2006 Sept 4. PMID: 16953228.
  130. Yang G, Rosen DG, Zhang Z, Bast RC Jr, Mills GB, Colacino JA, Mercado-Uribe I, Liu J. The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16472-7. Epub 2006 Oct 23. PMCID: PMC1637606.
  131. Schmeler KM, Sun CC, Bodurka DC, White KG, Soliman PT, Uyei AR, Erlichman JL, Arun BK, Daniels MS, Rimes SA, Peterson SK, Slomovitz BM, Milam MR, Gershenson DM, Lu KH. Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations. Obstet Gynecol. 2006 Sep;108(3 Pt 1):515-20. PMID: 16946209.
  132. Kamat AA, Sood AK, Dang D, Gershenson DM, Simpson JL, Bischoff FZ. Quantification of total plasma cell-free DNA in ovarian cancer using real-time PCR. Ann N Y Acad Sci. 2006 Sep;1075:230-4. PMID: 17108216.
  133. Landen CN, Merritt WM, Mangala LS, Sanguino AM, Bucana C, Lu C, Lin YG, Han LY, Kamat AA, Schmandt R, Coleman RL, Gershenson DM, Lopez-Berestein G, Sood AK. Intraperitoneal Delivery of Liposomal siRNA for Therapy of Advanced Ovarian Cancer. Cancer Biol Ther. 2006 Dec;5(12):1708-13. Epub 2006 Dec 30. PMID: 17106249.
  134. Lorenzi PL, Reinhold WC, Rudelius M, Gunsior M, Shankavaram U, Bussey KJ, Scherf U, Eichler GS, Martin SE, Chin K, Gray JW, Kohn EC, Horak ID, Von Hoff DD, Raffeld M, Goldsmith PK, Caplen NJ, Weinstein JN. Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells. Mol Cancer Ther. 2006 Nov;5(11):2613-23. Epub 2006 Nov 6. PMID: 17088436.
  135. Shih IeM, Salani R, Fiegl M, Wang TL, Soosaipillai A, Marth C, Müller-Holzner E, Gastl G, Zhang Z, Diamandis EP. Ovarian cancer specific kallikrein profile in effusions. Gynecol Oncol. 2007 May;105(2):501-7. Epub 2007 Feb 15. PMID: 17303231.
  136. Young TW, Mei FC, Rosen DG, Yang G, Li N, Liu J, Cheng X. Up-regulation of tumor susceptibility gene 101 protein in ovarian carcinomas revealed by proteomic analyses. Mol Cell Proteomics. 2007 Feb;6(2):294-304. Epub 2006 Nov 16. PMID: 17110434.
  137. Yang G, Rosen DG, Mercado-Uribe I, Colacino JA, Mills GB, Bast RC Jr, Zhou C, Liu J. Knockdown of p53 combined with expression of the catalytic subunit of telomerase is sufficient to immortalize primary human ovarian surface epithelial cells. Carcinogenesis. 2007 Jan;28(1):174-82. Epub 2006 Jul 8. PMID: 16829690.
  138. Gershenson DM, Sun CC, Lu KH, Coleman RL, Sood AK, Malpica A, Deavers MT, Silva EG, Bodurka DC. Clinical Behavior of Stage II-IV Low-Grade Serous Carcinoma of the Ovary. Obstet Gynecol. 2006 Aug;108(2):361-8. PMID: 16880307.
  139. Coleman RL, Broaddus RR, Bodurka DC, Wolf JK, Burke TW, Kavanagh JJ, Levenback CF, Gershenson DM. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecol Oncol. 2006 Apr;101(1):126-31. Epub 2005 Nov 3. PMID: 16271384.
  140. Gossner G, Coleman RL, Mutch DG, Horowitz NS, Rader JS, Gibb RK, Powell MA, Herzog TJ. CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan. Gynecol Oncol. 2006 Oct;103(1):212-8. Epub 2006 May 3. PMID: 16677696.
  141. Balkwill FR, Ashworth A, Bast RC, Berek JS, Boyd J, Disis ML, Gabra H, Gore ME, Hamilton TC, Jacobs IJ, Kaye SB, Kohn EC, Mills GB, Urban ND. 10th Biennial Helene Harris Memorial Trust meeting. Cancer Res. 2006 Mar 15;66(6):2904-6. PMID: 16540635.
  142. Lutgendorf SK, Sood AK, Anderson B, McGinn S, Maiseri H, Dao M, Sorosky JI, De Geest K, Ritchie J, Lubaroff DM. Social support, psychological distress, and natural killer cell activity in ovarian cancer. J Clin Oncol. 2005 Oct 1;23(28):7105-13. PMID: 16192594.
  143. Landen CN Jr, Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez-Berestein G, SoodAK. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 2005 Aug 1;65(15):6910-8. PMID: 16061675.
  144. Sood AK, Coleman RL, Wolf JK, Gershenson DM. Selected highlights from the 5th International Conference on Ovarian Cancer. Houston, TX, USA, 1-4 December 2004. Expert Opin Pharmacother. 2005 Jul;6(7):1269-75. No abstract available. PMID: 15957979.
  145. Costanzo ES, Lutgendorf SK, Sood AK, Anderson B, Sorosky J, Lubaroff DM. Psychosocial factors and interleukin-6 among women with advanced ovarian cancer. Cancer. 2005 Jul 15;104(2):305-13. PMID: 15954082.
  146. Sood AK, Abu-Rustum NR, Barakat RR, Bodurka DC, Brown J, Donato ML, Poynor EA, Wolf JK, Gershenson DM. Fifth International Conference on Ovarian Cancer: challenges and opportunities. Gynecol Oncol. 2005 Jun;97(3):916-23. PMID: 15907981.
  147. Cheng KW, Lahad JP, Gray JW, Mills GB. Emerging role of Rab GTPases in cancer and human disease: Cancer Res 2005 Apr 1;65(7):2516-9. PMID: 15805241.
  148. Wang X, Wang E, Kavanagh JJ, Freedman RS. Ovarian cancer, the coagulation pathway, and inflammation. J Transl Med. 2005 Jun 21;3:25. PMCID: PMC1182397.
  149. Hennessy BT, Mills GB. Ovarian cancer: Homeobox genes, autocrine/paracrine growth, and kinase signaling. Int J Biochem Cell Biol. 2006 Sep;38(9):1450-6. Epub 2006 Feb 21. PMID: 16682246.
  150. Gershenson DM. Fertility-sparing surgery for malignancies in women. J Natl Cancer Inst Monogr. 2005;(34):43-7. Review. PMID: 15784822.
  151. Brewer M, Ranger-Moore J, Satterfield W, Hao Z, Wang J, Brewer E, Wharton JT, Bast R, Zou C. Combination of 4-HPR and oral contraceptive in monkey model of chemoprevention of ovarian cancer. Front Biosci. 2007 Jan 1;12:2260-8. PMID: 17127462.
  152. Coleman RL. Intraperitoneal chemotherapy for frontline ovarian cancer therapy: vindicated or vilified? Curr Oncol Rep. 2006 Nov;8(6):439-440. No abstract available. PMID: 17091543.
  153. Rodabaugh KJ, Mhawech-Fauceglia P, Groth J, Lele S, Sood AK. Prostate-derived Ets Factor Is Overexpressed in Serous Epithelial Ovarian Tumors. Int J Gynecol Pathol. 2007 Jan;26(1):10-15. PMID: 17197890.
  154. Sood AK. Second look laparotomy for ovarian germ cell tumors: to do or not to do? J Postgrad Med. 2006 Oct-Dec;52(4):246-7. No abstract available. PMID: 17191357.
  155. Nakayama K, Ueno NT. American Society of Clinical Oncology recommendations on fertility preservation should be implemented regardless of disease status or previous treatments. J Clin Oncol. 2006 Nov 20;24(33):5334-5; author reply 5337-8. PMID: 17114671.
  156. Uyei A, Peterson SK, Erlichman J, Broglio K, Yekell S, Schmeler K, Lu K, Meric-Bernstam F, Amos C, Strong L, Arun B. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study. Cancer. 2006 Dec 15;107(12):2745-51. Epub 2006 Nov 15. PMID: 17109443.
  157. Stilwell JL, Guan Y, Neve RM, Gray JW. Systems biology in cancer research: genomics to cellomics. Methods Mol Biol. 2007;356:353-65. PMID: 16988415.
  158. Coleman RL. 7th annual International Conference on Ovarian Cancer. Expert Rev Anticancer Ther. 2007 Feb;7(2):119-21. No abstract available. PMID: 17288523.
  159. Thaker PH, Lutgendorf SK, Sood AK. The neuroendocrine impact of chronic stress on cancer. Cell Cycle. 2007 Feb;6(4):430-3. Epub 2007 Feb 9. Review. PMID: 17312398.
  160. Milam MR, Sood AK, King S, Bassett RL Jr, Lu KH, Slomovitz BM, Coleman RL, Ramirez PT. Supracervical hysterectomy in patients with advanced epithelial ovarian cancer. Obstet Gynecol. 2007 Mar;109(3):641-6. PMID: 17329515.
  161. Saucier JM, Yu J, Gaikwad A, Coleman RL, Wolf JK, Smith JA. Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model. J Oncol Pharm Pract. 2007 Mar;13(1):39-45. PMID: 17621566.
  162. Spannuth WA, Thaker PH, Sood AK. Concomitant BRCA1 and BRCA2 gene mutations in an Ashkenazi Jewish woman with primary breast and ovarian cancer. Am J Obstet Gynecol. 2007 Apr;196(4):e6-9. PMID: 17403394.
  163. Ishiyama S, Matsueda S, Jones LA, Efferson C, Celestino J, Schmandt R, Ioannides CG, Tsuda N, Chang DZ. Novel natural immunogenic peptides from Numb1 and Notch1 proteins for CD8+ cells in ovarian ascites. Int J Oncol. 2007 Apr;30(4):889-98. PMID: 17332928.
  164. Crotzer DR, Wolf JK, Gano JB, Gershenson DM, Levenback C. A pilot study of cisplatin, ifosfamide and mesna in the treatment of malignant mixed mesodermal tumors of the ovary. Gynecol Oncol. 2007 May;105(2):399-403. Epub 2007 Feb 9. PMID: 17292457.
  165. Crotzer DR, Sun CC, Coleman RL, Wolf JK, Levenback CF, Gershenson DM. Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol. 2007 May;105(2):404-8. Epub 2007 Feb 9. PMID: 17292461.
  166. Li P, Maines-Bandiera S, Kuo WL, Guan Y, Sun Y, Hills M, Huang G, Collins CC, Leung PC, Gray JW, Auersperg N. Multiple roles of the candidate oncogene ZNF217 in ovarian epithelial neoplastic progression. Int J Cancer. 2007 May 1;120(9):1863-73. PMID: 17266044.
  167. Champion V, Williams SD, Miller A, Reuille KM, Wagler-Ziner K, Monahan PO, Zhao Q, Gershenson D, Cella D; Gynecologic Oncology Group. Quality of life in long-term survivors of ovarian germ cell tumors: a Gynecologic Oncology Group study. Gynecol Oncol. 2007 Jun;105(3):687-94. Epub 2007 Mar 13. PMCID: PMC1995655.
  168. Shvartsman HS, Sun CC, Bodurka DC, Mahajan V, Crispens M, Lu KH, Deavers MT, Malpica A, Silva EG, Gershenson DM. Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma. Gynecol Oncol. 2007 Jun;105(3):625-9. Epub 2007 Feb 22. PMID: 17320156.
  169. Chiesa-Vottero AG, Malpica A, Deavers MT, Broaddus R, Nuovo GJ, Silva EG. Immunohistochemical Overexpression of p16 and p53 in Uterine Serous Carcinoma and Ovarian High-grade Serous Carcinoma. Int J Gynecol Pathol. 2007 Jul;26(3):328-333. PMID: 17581420.
  170. Gershenson DM, Miller AM, Champion VL, Monahan PO, Zhao Q, Cella D, Williams SD; Gynecologic Oncology Group. Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group Study. J Clin Oncol. 2007 Jul 1;25(19):2792-7. PMID: 17602084.
  171. Gershenson DM, Birrer M. Time for action: A "sea change" in treatment strategies for rare types of epithelial ovarian cancer. Gynecol Oncol. 2007 Jul;106(1):1-3. PMID: 17574071.
  172. Gershenson DM. Management of ovarian germ cell tumors. J Clin Oncol. 2007 Jul 10;25(20):2938-43. Review. PMID: 17617525.
  173. Young TW, Rosen DG, Mei FC, Li N, Liu J, Wang XF, Cheng X. Up-regulation of tumor susceptibility gene 101 conveys poor prognosis through suppression of p21 expression in ovarian cancer. Clin Cancer Res. 2007 Jul 1;13(13):3848-54. PMID: 17606716.
  174. Jaishuen A, Berrios-Rivera JP, Sirisabya N, Zheng HG, Li Y, Kavanagh JJ. Erosive osteoarthritis during treatment with bevacizumab and paclitaxel in a patient with recurrent papillary serous carcinoma of the ovary. Int J Gynecol Cancer. 2008 Mar-Apr;18(2):379-83. Epub 2007 Jul 11. PMID: 17624988.
  175. Lamkin DM, Lutgendorf SK, McGinn S, Dao M, Maiseri H, Degeest K, Sood AK, Lubaroff DM. Positive psychosocial factors and NKT cells in ovarian cancer patients. Brain Behav Immun. 2008 Jan;22(1):65-73. Epub 2007 Jul 23. PMID: 17643954.
  176. Kavanagh JJ. Intraperitoneal chemotherapy in the treatment of ovarian cancer. J Surg Oncol. 2007 Dec 1;96(7):541-2. No abstract available. PMID: 17654524.
  177. Li Y, Finkel KW, Hu W, Fu S, Liu J, Coleman R, Kavanagh JJ. Pegylated liposomal doxorubicin treatment in recurrent gynecologic cancer patients with renal dysfunction. Gynecol Oncol. 2007 Aug;106(2):375-80. Epub 2007 May 18. PMID: 17512575.
  178. Nilsson MB, Armaiz-Pena G, Takahashi R, Lin YG, Trevino J, Li Y, Jennings N, Arevalo J, Lutgendorf SK, Gallick GE, Sanguino AM, Lopez-Berestein G, Cole SW, Sood AK. Stress hormones regulate IL-6 expression by human ovarian carcinoma cells through a SRC-dependent mechanism. J Biol Chem. 2007 Oct 12;282(41):29919-26. Epub 2007 Aug 23. PMID: 17716980.
  179. Zhang Z, Singh M, Davidson S, Rosen DG, Yang G, Liu J. Activation of BTAK expression in primary ovarian surface epithelial cells of prophylactic ovaries. Mod Pathol. 2007 Oct;20(10):1078-84. Epub 2007 Aug 3. PMID: 17673924.
  180. Bast RC Jr. How Do You Distinguish a Malignant Pelvic Mass From a Benign Pelvic Mass? Imaging, Biomarkers, or None of the Above. J Clin Oncol. 2007 Sep 20;25(27):4159-61. Epub 2007 Aug 13. No abstract available. PMID: 17698803.
  181. Bedrosian I, Lee C, Tucker SL, Palla SL, Lu K, Keyomarsi K. Cyclin E-associated kinase activity predicts response to platinum-based chemotherapy. Clin Cancer Res. 2007 Aug 15;13(16):4800-6. PMID: 17699858.
  182. Ramirez PT, Landen CN Jr, Coleman RL, Milam MR, Levenback C, Johnston TA, Gershenson DM. Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer. Gynecol Oncol. 2008 Jan;108(1):68-71. Epub 2007 Oct 1. PMID: 17905421.
  183. Sirisabya N, Li Y, Jaishuen A, Zheng HG, Gershenson DM, Kavanagh JJ. Tamoxifen is safe and effective in gynecological cancer patients with renal dysfunction. Int J Gynecol Cancer. 2008 Jul-Aug;18(4):648-51. Epub 2007 Sep 24. PMID: 17892459.
  184. Kim TJ, Ravoori M, Landen CN, Kamat AA, Han LY, Lu C, Lin YG, Merritt WM, Jennings N, Spannuth WA, Langley R, Gershenson DM, Coleman RL, Kundra V, Sood AK. Antitumor and Antivascular Effects of AVE8062 in Ovarian Carcinoma. Cancer Res. 2007 Oct 1;67(19):9337-45. PMID: 17909042.
  185. Feng W, Marquez RT, Lu Z, Liu J, Lu KH, Issa JP, Fishman DM, Yu Y, Bast RC Jr. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer. 2008 Apr 1;112(7):1489-502. PMID: 18286529.
  186. Press JZ, De Luca A, Boyd N, Young S, Troussard A, Ridge Y, Kaurah P, Kalloger SE, Blood KA, Smith M, Spellman PT, Wang Y, Miller DM, Horsman D, Faham M, Gilks CB, Gray J, Huntsman DG. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer. 2008 Jan 22;8:17. PMCID: PMC2245962.
  187. Saldivar JS, Lu KH, Liang D, Gu J, Huang M, Vlastos AT, Follen M, Wu X. Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients. Gynecol Oncol. 2007 Oct;107(1 Suppl 1):S223-9. Epub 2007 Sep 6. PMID: 17825393.
  188. Saldivar JS, Wu X, Follen M, Gershenson D. Nucleotide excision repair pathway review I: implications in ovarian cancer and platinum sensitivity. Gynecol Oncol. 2007 Oct;107(1 Suppl 1):S56-71. Epub 2007 Sep 19. Review. PMID: 17884153.
  189. Schmeler KM, Sun CC, Bodurka DC, Deavers MT, Malpica A, Coleman RL, Ramirez PT, Gershenson DM. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol. 2008 Mar;108(3):510-4. Epub 2007 Dec 26. PMID: 18155273.
  190. Wong KK, Gershenson D. The continuum of serous tumors of low malignant potential and low-grade serous carcinomas of the ovary. Dis Markers. 2007;23(5-6):377-87. Review. PMID: 18057521.
  191. Zecchini S, Bianchi M, Colombo N, Fasani R, Goisis G, Casadio C, Viale G, Liu J, Herlyn M, Godwin AK, Nuciforo PG, Cavallaro U. The differential role of L1 in ovarian carcinoma and normal ovarian surface epithelium. Cancer Res. 2008 Feb 15;68(4):1110-8. PMID: 18281486.
  192. Bennett P, Wilkinson C, Turner J, Brain K, Edwards RT, Griffith G, France B, Gray J. Psychological Factors Associated with Emotional Responses to Receiving Genetic Risk Information. J Genet Couns. 2008 Jun;17(3):234-41. Epub 2008 Feb 8. PMID: 18259848.
  193. Lancaster JM, Bethan Powell C, Kauff ND, Cass I, Chen LM, Lu KH, Mutch DG, Berchuck A, Karlan BY, Herzog TJ; for the Society of Gynecologic Oncologists Hereditary Cancer Education Resource Panel. Society of gynecologic oncologists education committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. 2007 Nov;107(2):159-62. PMID: 17950381.
  194. Liu S, Fang X, Hall H, Yu S, Smith D, Lu Z, Fang D, Liu J, Stephens LC, Woodgett JR, Mills GB. Homozygous deletion of glycogen synthase kinase 3beta bypasses senescence allowing Ras transformation of primary murine fibroblasts. Proc Natl Acad Sci U S A. 2008 Apr 1;105(13):5248-53. Epub 2008 Mar 26. PMCID: PMC2278194.
  195. Murph M, Tanaka T, Pang J, Felix E, Liu S, Trost R, Godwin AK, Newman R, Mills G. Liquid chromatography mass spectrometry for quantifying plasma lysophospholipids: potential biomarkers for cancer diagnosis. Methods Enzymol. 2007;433:1-25. PMID: 17954226.
  196. Raphael BJ, Volik S, Yu P, Wu C, Huang G, Linardopoulou EV, Trask BJ, Waldman FM, Costello J, Pienta KJ, Mills GB, Bajsarowicz K, Kobayashi Y, Shivaranjani S, Paris P, Tao Q, Aerni SJ, Brown RP, Bashir A, Gray JW, Cheng JF, de Jong P, Nefedov M, Ried T, Padilla-Nash HM, Collins CC. A sequence-based survey of the complex structural organization of tumor genomes. Genome Biol. 2008;9(3):R59. Epub 2008 Mar 25. PMCID: PMC2397511.
  197. Chi DS, Ramirez PT, Teitcher JB, Mironov S, Sarasohn DM, Iyer RB, Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Levine DA, Brown CL, Aghajanian C, Gershenson DM, Hoskins WJ, Hricak H, Barakat RR. Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease 1 cm or less. J Clin Oncol. 2007 Nov 1;25(31):4946-51. PMID: 17971592.
  198. Coleman RL. Gemcitabine plus Carboplatin Compared with Carboplatin Alone for Platinum-sensitive Recurrent Ovarian Cancer. Curr Oncol Rep. 2007 Nov;9(6):469-71. PMID: 17991354.
  199. Coleman RL, Gordon A, Barter J, Sun S, Rackoff W, Herzog TJ. Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients. Oncologist. 2007 Jan;12(1):72-8. PMID: 17227902.
  200. Boruban MC, Jaishuen A, Sirisabya N, Li Y, Zheng HG, Deavers MT, Kavanagh JJ. Ovarian endometriosis associated with carcinoma and sarcoma: case report. Eur J Gynaecol Oncol. 2008;29(4):393-6. PMID: 18714578.
  201. Coleman RL, Kohn EC. Rationale for combination use of targeted agents in ovarian cancer: do we have one? Cancer. 2008 Aug 15;113(4):665-7. PMID: 18623195.
  202. Dimple C, Nair SS, Rajhans R, Pitcheswara PR, Liu J, Balasenthil S, Le XF, Burow ME, Auersperg N, Tekmal RR, Broaddus RR, Vadlamudi RK. Role of PELP1/MNAR signaling in ovarian tumorigenesis. Cancer Res. 2008 Jun 15;68(12):4902-9. PMID: 18559538.
  203. Han LY, Fletcher MS, Urbauer DL, Mueller P, Landen CN, Kamat AA, Lin YG, Merritt WM, Spannuth WA, Deavers MT, De Geest K, Gershenson DM, Lutgendorf SK, Ferrone S, Sood AK. HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin Cancer Res. 2008 Jun 1;14(11):3372-9. PMID: 18519766.
  204. Hennessy BT, Murph M, Nanjundan M, Carey M, Auersperg N, Almeida J, Coombes KR, Liu J, Lu Y, Gray JW, Mills GB. Ovarian cancer: linking genomics to new target discovery and molecular markers--the way ahead. Adv Exp Med Biol. 2008;617:23-40. Review. PMID: 18497028.
  205. Hwang JY, Mangala LS, Fok JY, Lin YG, Merritt WM, Spannuth WA, Nick AM, Fiterman DJ, Vivas-Mejia PE, Deavers MT, Coleman RL, Lopez-Berestein G, Mehta K, Sood AK. Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Res. 2008 Jul 15;68(14):5849-58. PMCID: PMC2547344.
  206. Kavanagh JJ, Sill MW, Ramirez PT, Warshal D, Pearl ML, Morgan MA. Phase II multicenter open-label study of karenitecin in previously treated epithelial ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Int J Gynecol Cancer. 2008 May-Jun;18(3):460-4. Epub 2007 Sep 13. PMID: 17854432.
  207. Kubba LA, McCluggage WG, Liu J, Malpica A, Euscher ED, Silva EG, Deavers MT. Thyroid transcription factor-1 expression in ovarian epithelial neoplasms. Mod Pathol. 2008 Apr;21(4):485-90. Epub 2008 Feb 1. PMID: 18246044.
  208. Kwon JS, Sun CC, Peterson SK, White KG, Daniels MS, Boyd-Rogers SG, Lu KH. Cost-effectiveness analysis of prevention strategies for gynecologic cancers in Lynch syndrome. Cancer. 2008 Jul 15;113(2):326-35. PMID: 18506736.
  209. Lacour RA, Daniels MS, Westin SN, Meyer LA, Burke CC, Burns KA, Kurian S, Webb NF, Pustilnik TB, Lu KH. What women with ovarian cancer think and know about genetic testing. Gynecol Oncol. 2008 Oct;111(1):132-6. Epub 2008 Aug 6. PMID: 18684498.
  210. Lu KH. Hereditary gynecologic cancers: differential diagnosis, surveillance, management and surgical prophylaxis. Fam Cancer. 2008;7(1):53-8. Epub 2007 Jul 17. Review. PMID: 17636427.
  211. Lutgendorf SK, Lamkin DM, DeGeest K, Anderson B, Dao M, McGinn S, Zimmerman B, Maiseri H, Sood AK, Lubaroff DM. Depressed and anxious mood and T-cell cytokine expressing populations in ovarian cancer patients. Brain Behav Immun. 2008 Aug;22(6):890-900. Epub 2008 Feb 13. PMCID: PMC2605940.
  212. Lutgendorf SK, Weinrib AZ, Penedo F, Russell D, Degeest K, Costanzo ES, Henderson PJ, Sephton SE, Rohleder N, Lucci JA 3rd, Cole S, Sood AK, Lubaroff DM. Interleukin-6, Cortisol, and Depressive Symptoms in Ovarian Cancer Patients. J Clin Oncol. 2008 Oct 10;26(29):4820-7. Epub 2008 Sep 8. PMCID: PMC2653140.
  213. Nick AM, Sood AK. The ROC 'n' role of the multiplex assay for early detection of ovarian cancer. Nat Clin Pract Oncol. 2008 Oct;5(10):568-9. Epub 2008 Aug 12. PMID: 18695710.
  214. Ramirez PT, Schmeler KM, Milam MR, Slomovitz BM, Smith JA, Kavanagh JJ, Deavers M, Levenback C, Coleman RL, Gershenson DM. Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum. Gynecol Oncol. 2008 Jul;110(1):56-9. Epub 2008 May 5. PMID: 18457865.
  215. Ramus SJ, Elmasry K, Luo Z, Gammerman A, Lu K, Ayhan A, Singh N, McCluggage WG, Jacobs IJ, Whittaker JC, Gayther SA. Predicting clinical outcome in patients diagnosed with synchronous ovarian and endometrial cancer. Clin Cancer Res. 2008 Sep 15;14(18):5840-8. PMID: 18794095.
  216. Schmeler KM, Lu KH. Gynecologic cancers associated with Lynch syndrome/HNPCC. Clin Transl Oncol. 2008 Jun;10(6):313-7. Review. PMID: 18558577.
  217. Smith JA, Gaikwad A, Yu J, Wolf JK, Brown J, Ramondetta LM, Stewart CF. In vitro evaluation of the effects of gefitinib on the modulation of cytotoxic activity of selected anticancer agents in a panel of human ovarian cancer cell lines. Cancer Chemother Pharmacol. 2008 Jun;62(1):51-8. Epub 2007 Sep 12. PMID: 17849119.
  218. Stany MP, Bonome T, Wamunyokoli F, Zorn K, Ozbun L, Park DC, Hao K, Boyd J, Sood AK, Gershenson DM, Berkowitz RS, Mok SC, Birrer MJ. Classification of ovarian cancer: a genomic analysis. Adv Exp Med Biol. 2008;622:23-33. Review. PMID: 18546616.
  219. Sun Y, Wong N, Guan Y, Salamanca CM, Cheng JC, Lee JM, Gray JW, Auersperg N. The eukaryotic translation elongation factor eEF1A2 induces neoplastic properties and mediates tumorigenic effects of ZNF217 in precursor cells of human ovarian carcinomas. Int J Cancer. 2008 Oct 15;123(8):1761-9. PMCID: PMC2606039.
  220. Wang D, Zhao Z, Caperell-Grant A, Yang G, Mok SC, Liu J, Bigsby RM, Xu Y. S1P differentially regulates migration of human ovarian cancer and human ovarian surface epithelial cells. Mol Cancer Ther. 2008 Jul;7(7):1993-2002. PMCID: PMC2649755.
  221. Wang X, Urvalek AM, Liu J, Zhao J. Activation of KLF8 transcription by focal adhesion kinase in human ovarian epithelial and cancer cells. J Biol Chem. 2008 May 16;283(20):13934-42. Epub 2008 Mar 19. PMID: 18353772.
  222. Wei Y, Xia W, Zhang Z, Liu J, Wang H, Adsay NV, Albarracin C, Yu D, Abbruzzese JL, Mills GB, Bast RC Jr, Hortobagyi GN, Hung MC. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog. 2008 Sep;47(9):701-6. PMCID: PMC2580832.
  223. Zhai QJ, Rosen DG, Lu K, Liu J. Loss of DNA Mismatch Repair Protein hMSH6 in Ovarian Cancer is Histotype-Specific. Int J Clin Exp Pathol. 2008 Jan 31;1(6):502-9. PMCID: PMC2480583.
  224. Gajewiak J, Tsukahara R, Tsukahara T, Yu S, Lu Y, Murph M, Mills GB, Tigyi G, Prestwich GD. Alkoxymethylenephosphonate analogues of (Lyso) phosphatidic acid stimulate signaling networks coupled to the LPA2 receptor. ChemMedChem. 2007 Dec;2(12):1789-98. PMID: 17952880.
  225. Herzog TJ, Powell MA, Rader JS, Gibb RK, Lippmann L, Coleman RL, Mutch DG. Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer. Gynecol Oncol. 2008 Dec;111(3):467-73. Epub 2008 Oct 1. PMID: 18834619.
  226. Schmeler KM, Gershenson DM. Low-grade serous ovarian cancer: a unique disease. Curr Oncol Rep. 2008 Nov;10(6):519-23. PMID: 18928667.
  227. Lu Z, Luo RZ, Lu Y, Zhang X, Yu Q, Khare S, Kondo S, Kondo Y, Yu Y, Mills GB, Liao WS, Bast RC Jr. The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. J Clin Invest. 2008 Dec;118(12):3917-29. Epub 2008 Nov 20. PMCID: PMC2582930.
  228. Bartholomeusz C, Rosen D, Wei C, Kazansky A, Yamasaki F, Takahashi T, Itamochi H, Kondo S, Liu J, Ueno NT. PEA-15 induces autophagy in human ovarian cancer cells and is associated with prolonged overall survival. Cancer Res. 2008 Nov 15;68(22):9302-10. PMCID: PMC2676677.
  229. Morgan RJ Jr, Alvarez RD, Armstrong DK, Boston B, Chen LM, Copeland L, Fowler J, Gaffney DK, Gershenson D, Greer BE, Grigsby PW, Havrilesky LJ, Johnston C, Lancaster JM, Lele S, Matulonis U, O'Malley D, Ozols RF, Remmenga SW, Sabbatini P, Schink J, Teng N; National Comprehensive Cancer Network. Ovarian cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2008 Sep;6(8):766-94. No abstract available. PMID: 18926089.
  230. Xia W, Wei Y, Du Y, Liu J, Chang B, Yu YL, Huo LF, Miller S, Hung MC. Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer. Mol Carcinog. 2009 Jul;48(7):610-7. PMCID: PMC2718429.
  231. Song J, Shih LM, Salani R, Chan DW, Zhang Z. Annexin XI is associated with cisplatin resistance and related to tumor recurrence in ovarian cancer patients. Clin Cancer Res 2007; 13(22):6842-49. PMID: 17982121.
  232. Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, Spannuth WA, Tanaka T, Shahzad MM, Lin YG, Nick AM, Danes CG, Lee JW, Jennings NB, Vivas-Mejia PE, Wolf JK, Coleman RL, Siddik ZH, Lopez-Berestein G, Lutsenko S, Sood AK. Therapeutic Targeting of ATP7B in ovarian carcinoma. Clin Cancer Res. 2009 Jun 1;15(11):3770-80. Epub 2009 May 26. PMID: 19470734.
  233. Murph MM, Liu W, Yu S, Lu Y, Hall H, Hennessy BT, Lahad J, Schaner M, Helland A, Kristensen G, Børresen-Dale AL, Mills GB. Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis. PLoS ONE. 2009;4(5):e5583. Epub 2009 May 15. PMCID: PMC2679144.
  234. Tanyi JL, Smith JA, Ramos L, Parker CL, Munsell MF, Wolf JK. Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer. Gynecol Oncol. 2009 Aug;114(2):219-24. Epub 2009 May 17. PMID: 19446868.
  235. Armaiz-Pena GN, Mangala LS, Spannuth WA, Lin YG, Jennings NB, Nick AM, Langley RR, Schmandt R, Lutgendorf SK, Cole SW, Sood AK. Estrous Cycle Modulates Ovarian Carcinoma Growth. Clin Cancer Res. 2009 May 1;15(9):2971-8. Epub 2009 Apr 21. PMID: 19383821.
  236. Brown J, Sood AK, Deavers MT, Milojevic L, Gershenson DM. Patterns of metastasis in sex cord-stromal tumors of the ovary: Can routine staging lymphadenectomy be omitted? Gynecol Oncol. 2009 Apr;113(1):86-90. Epub 2009 Jan 21. PMID: 19162310.
  237. Chang B, Liu G, Xue F, Rosen DG, Xiao L, Wang X, Liu J. ALDH1 expression correlates with favorable prognosis in ovarian cancers. Mod Pathol. 2009 Jun;22(6):817-23. Epub 2009 Mar 27. PMCID: PMC2692456.
  238. Chang B, Liu G, Yang G, Mercado-Uribe I, Huang M, Liu J. REDD1 is required for RAS-mediated transformation of human ovarian epithelial cells. Cell Cycle. 2009 Mar 1;8(5):780-6. Epub 2009 Mar 20. PMID: 19221489.
  239. Gershenson DM, Sun CC, Bodurka D, Coleman RL, Lu KH, Sood AK, Deavers M, Malpica AL, Kavanagh JJ. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol. 2009 Jul;114(1):48-52. Epub 2009 Apr 10. PMID: 19361839.
  240. Lamkin DM, Spitz DR, Shahzad MM, Zimmerman B, Lenihan DJ, Degeest K, Lubaroff DM, Shinn EH, Sood AK, Lutgendorf SK. Glucose as a prognostic factor in ovarian carcinoma. Cancer. 2009 Mar 1;115(5):1021-7. PMCID: PMC2649990.
  241. Lee JW, Shahzad MM, Lin YG, Armaiz-Pena G, Mangala LS, Han HD, Kim HS, Nam EJ, Jennings NB, Halder J, Nick AM, Stone RL, Lu C, Lutgendorf SK, Cole SW, Lokshin AE, Sood AK. Surgical stress promotes tumor growth in ovarian carcinoma. Clin Cancer Res. 2009 Apr 15;15(8):2695-702. Epub 2009 Apr 7. PMID: 19351748.
  242. Lutgendorf SK, DeGeest K, Sung CY, Arevalo JM, Penedo F, Lucci J 3rd, Goodheart M, Lubaroff D, Farley DM, Sood AK, Cole SW. Depression, social support, and beta-adrenergic transcription control in human ovarian cancer. Brain Behav Immun. 2009 Feb;23(2):176-83. Epub 2008 Jun 11. PMCID: PMC2677379.
  243. Matsumura N, Huang Z, Baba T, Lee PS, Barnett JC, Mori S, Chang JT, Kuo WL, Gusberg AH, Whitaker RS, Gray JW, Fujii S, Berchuck A, Murphy SK. Yin yang 1 modulates taxane response in epithelial ovarian cancer. Mol Cancer Res. 2009 Feb;7(2):210-20. Epub 2009 Feb 10. PMCID: PMC2675878.
  244. Monahan PO, Champion VL, Zhao Q, Miller AM, Gershenson D, Williams SD, Cella D. Case-control comparison of quality of life in long-term ovarian germ cell tumor survivors: a gynecologic oncology group study. J Psychosoc Oncol. 2008;26(3):19-42. PMID: 19042263.
  245. Nanjundan M, Cheng KW, Zhang F, Lahad J, Kuo WL, Schmandt R, Smith-McCune K, Fishman D, Gray JW, Mills GB. Overexpression of SnoN/SkiL, amplified at the 3q26.2 locus, in ovarian cancers: a role in ovarian pathogenesis. Mol Oncol. 2008 Aug;2(2):164-81. Epub 2008 May 10. PMCID: PMC2598416.
  246. Rohozinski J, Anderson ML, Broaddus RE, Edwards CL, Bishop CE. Spermatogenesis associated retrogenes are expressed in the human ovary and ovarian cancers. PLoS ONE. 2009;4(3):e5064. Epub 2009 Mar 31. PMCID: PMC2660244.
  247. Rosen DG, Yang G, Liu G, Mercado-Uribe I, Chang B, Xiao XS, Zheng J, Xue FX, Liu J. Ovarian cancer: pathology, biology, and disease models. Front Biosci. 2009 Jan 1;14:2089-102. PMID: 19273186.
  248. Schmeler KM, Vadhan-Raj S, Ramirez PT, Apte SM, Cohen L, Bassett RL, Iyer RB, Wolf JK, Levenback CL, Gershenson DM, Freedman RS. A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer. Gynecol Oncol. 2009 May;113(2):210-5. Epub 2009 Mar 4. PMID: 19264351.
  249. Shan W, Liu J. Epithelial ovarian cancer: focus on genetics and animal models. Cell Cycle. 2009 Mar 1;8(5):731-5. Epub 2009 Mar 14. PMID: 19221485.
  250. Jandial DD, Soliman PT, Slomovitz BM, Schmeler KM, Levenback C, Coleman RL, Ramirez PT. Laparoscopic colostomy in gynecologic cancer. J Minim Invasive Gynecol. 2008 Nov-Dec;15(6):723-8. PMID: 18971136.
  251. Tao X, Kavanagh JJ. Chemotherapy for gynecological malignancies in organ transplantation patients: report of two cases. Int J Gynecol Cancer. 2008 Nov-Dec;18(6):1376-80. Epub 2008 May 6. PMID: 18462370.
  252. Agarwal R, Jurisica I, Mills GB, Cheng KW. The Emerging Role of the RAB25 Small GTPase in Cancer. Traffic. 2009 Jul 27. [Epub ahead of print]. PMID: 19719478.
  253. Daniels MS, Urbauer DL, Stanley JL, Johnson KG, Lu KH. Timing of BRCA1/BRCA2 genetic testing in women with ovarian cancer. Genet Med. 2009 Jul 14. [Epub ahead of print]. PMID: 19606053.
  254. Lee JW, Han HD, Shahzad MM, Kim SW, Mangala LS, Nick AM, Lu C, Langley RR, Schmandt R, Kim HS, Mao S, Gooya J, Fazenbaker C, Jackson D, Tice DA, Landen CN, Coleman RL, Sood AK. EphA2 Immunoconjugate as Molecularly Targeted Chemotherapy for Ovarian Carcinoma. J Natl Cancer Inst. 2009 Sep 2;101(17):1193-205. Epub 2009 Jul 29. PMID: 19641174.
  255. Matei D, Miller AM, Monahan P, Gershenson D, Zhao Q, Cella D, Champion VL, Williams SD. Chronic Physical Effects and Health Care Utilization in Long-Term Ovarian Germ Cell Tumor Survivors: A Gynecologic Oncology Group Study. J Clin Oncol. 2009 Jul 27. [Epub ahead of print]. PMID: 19636015.
  256. Samanta AK, Huang HJ, Le XF, Mao W, Lu KH, Bast RC Jr, Liao WS. MEKK3 expression correlates with nuclear factor kappa B activity and with expression of antiapoptotic genes in serous ovarian carcinoma. Cancer. 2009 Sep 1;115(17):3897-908. PMID: 19517469.
  257. Song J, Shih IeM, Chan DW, Zhang Z. Suppression of annexin A11 in ovarian cancer: implications in chemoresistance. Neoplasia. 2009 Jun;11(6):605-14, 1 p following 614. paxPMCID: PMC2685449.
  258. Tao X, Sood AK, Deavers MT, Schmeler KM, Nick AM, Coleman RL, Milojevic L, Gershenson DM, Brown J. Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors. Gynecol Oncol. 2009 Sep;114(3):431-6. Epub 2009 Jun 13. PMID: 19524286.
  259. Vergote I, Finkler N, Del Campo J, Lohr A, Hunter J, Matei D, Kavanagh J, Vermorken JB, Meng L, Jones M, Brown G, Kaye S; The ASSIST-1 Study Group. Phase 3 randomized study of canfosfamide (Telcyta((R)), TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer. Eur J Cancer. 2009 Jun 8. [Epub ahead of print]. PMID: 19515553.
  260. Huang S, Chang IS, Lin W, Ye W, Luo RZ, Lu Z, Lu Y, Zhang K, Liao WS, Tao T, Bast Jr RC, Chen X, Yu Y. ARHI (DIRAS 3), an imprinted tumor suppressor gene, binds to importins, and blocks nuclear import process of cargo proteins. Biosci Rep. 2009 May 13. [Epub ahead of print]. PMID: 19435463.
  261. Culton LK, Deavers MT, Silva EG, Liu J, Malpica A.  Endometrioid carcinoma simultaneously involving the uterus and the fallopian tube:  a clinicopathologic study of 13 cases.  Am J Surg Pathol 2006; 30: 844- 849. PMID: 16819326.
  262. Wang XH, Urvalek AM, Liu J, Zhao JH. Actvation of KLF8 transcription by FAK in human ovarian epithelial and cancer cells. J Biol Chem 2008; 283:13934-42. PMID: 18353772.
  263. Yeung BH, Kwan BW, He QY, Lee AS, Liu J, Wong AS. Glucose-regulated protein 78 as a novel effector of BRCA1 for inhibiting stress-induced apoptosis. Oncogene 2008; 27(53):6782-9. PMID: 18776923.
  264. Lu Z, Bast RC Jr. Tumor suppressor genes. Cancer Treat Res. 2009;149:109-29. PMID: 19763433.
  265. Xiao X, Yin H, Nguyen TB, Xiao J, Zhang H, Liu S, Yang G, Chen X, Zhang X, Liu J, Wang H. The anti-tumoral effect of Paris Saponin I is associated with the induction of apoptosis via a mitochondrial pathway. Mol Cancer Ther 2009 May 12. [Epub ahead of print]. PMID: 19435869.

© 2014 The University of Texas MD Anderson Cancer Center